Compare OXBR & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXBR | QNCX |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | Cayman Islands | United States |
| Employees | 4 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 6.9M |
| IPO Year | N/A | 2019 |
| Metric | OXBR | QNCX |
|---|---|---|
| Price | $0.77 | $1.37 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 1.3M | ★ 66.2M |
| Earning Date | 05-11-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $80.09 | N/A |
| Revenue Next Year | $85.22 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.08 |
| 52 Week High | $2.85 | $4.55 |
| Indicator | OXBR | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 43.77 | 80.74 |
| Support Level | $0.76 | $0.10 |
| Resistance Level | $1.42 | $2.05 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | -0.00 | 0.16 |
| Stochastic Oscillator | 15.20 | 94.94 |
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer that provides reinsurance solutions through its subsidiary. The company focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. It specializes in underwriting medium-frequency, high-severity risks where insufficient data exists to effectively analyze the risk/return profile of reinsurance contracts. The company generates revenue from three principal sources: premiums assumed from reinsurance on property and casualty business; income from investments, including unrealized gains or losses on other investments; and income from SurancePlus management fees.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.